Low testosterone in women is real, and it is often overlooked because testosterone gets filed away as a male hormone. Women make it too, in the ovaries and adrenal glands, and it contributes to libido, energy, mood, muscle, and bone. Levels decline with age and can drop sharply after the ovaries are removed. The symptoms of low testosterone in women are easy to miss because they overlap with so much else.
Yes, women need testosterone
Across a woman's reproductive years she actually produces more testosterone than estrogen by weight, measured as total daily output rather than blood concentration, though both circulate at far lower levels than testosterone does in men. It comes from two sources: the ovaries and the adrenal glands, plus conversion of precursor hormones in other tissues. Testosterone is not a bystander in female physiology. It supports sexual desire, contributes to lean muscle and bone density, and plays a role in energy and sense of wellbeing.
Female testosterone peaks in the twenties and declines gradually with age. By the time a woman reaches her forties, levels are often roughly half of what they were two decades earlier. This is normal aging, not disease, but it can still produce symptoms in some women.
Causes of low testosterone in women
Several things can push levels lower than expected:
- Age. The steady gradual decline described above.
- Surgical removal of the ovaries. Oophorectomy, often done with a hysterectomy, removes a major source of testosterone and causes an abrupt drop rather than a slow one.
- Adrenal insufficiency. Because the adrenals contribute, adrenal problems lower output.
- Certain medications. Oral estrogen, including some birth control pills, raises a binding protein called sex hormone binding globulin, which lowers the free, usable fraction of testosterone.
This last point matters. Total testosterone can look fine on paper while the bioavailable portion is low, which is one reason diagnosis is harder than just reading one number.
Symptoms of low testosterone in women
The symptoms are nonspecific, meaning they show up in many conditions, which is exactly why this gets missed:
- Low sexual desire, the most studied symptom, sometimes severe enough to qualify as hypoactive sexual desire disorder (HSDD)
- Persistent fatigue not explained by sleep or other illness
- Low mood or reduced sense of wellbeing
- Reduced muscle tone and difficulty maintaining strength
- Possible effects on bone density over time
Notice how much this overlaps with perimenopause, thyroid disease, depression, anemia, and burnout. A woman in her forties with fatigue and low libido could have any of those, alone or in combination. The same symptom list drives our piece on the 34 symptoms of perimenopause, and the overlap is not a coincidence. Sorting it out requires a clinician, not a checklist.
Why diagnosis is genuinely tricky
Here is the honest part most articles skip. The blood tests for testosterone were designed and validated for the higher levels seen in men. At the much lower concentrations normal in women, many standard assays become unreliable, and the same sample can read differently from one lab to another. There is no single agreed cutoff that defines low testosterone in a woman the way there is for male hypogonadism.
Because of that, the diagnosis leans on the clinical picture: symptoms first, with labs used as supporting information rather than the verdict. Free testosterone, the unbound usable fraction, tends to be more informative than total testosterone, and a clinician will interpret it alongside your symptoms, your history, and your other hormones. The baseline panel typically looks at the broader hormonal background, including thyroid and the binding globulin, not testosterone in isolation.
Timing and method add another layer. The 2019 consensus statement recommends measuring testosterone with the most sensitive assays available, because the cheaper methods perform worst exactly where women's levels sit. A blood draw should also be interpreted against where a woman is in her cycle or menopause transition. None of this means testing is useless. It means a single low or normal result, read in isolation, can mislead in both directions, and a clinician weighs it accordingly.
What the evidence supports for treatment
This is where rigor matters, because testosterone for women is heavily marketed and lightly regulated. The strongest evidence is narrow and specific. The 2019 Global Consensus Position Statement on the use of testosterone therapy for women, endorsed by several international menopause and endocrine societies, concluded that the only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women.
For that group, low-dose testosterone improved sexual desire and related outcomes. The same statement was clear about the limits. There is not enough evidence to recommend testosterone for fatigue, mood, bone, cognition, or general wellbeing on its own. It is not a fountain of youth, and the consensus said so directly.
A few practical points follow from that document:
- In the United States there is no testosterone product FDA-approved for women, so any use is off-label and should be carefully dosed.
- Dosing should keep blood levels within the normal premenopausal female range, not push them higher. Going above that range is what causes side effects like acne and unwanted hair growth.
- Levels should be monitored to confirm they stay in that physiologic window.
- For many women, the bigger hormonal picture of perimenopause or menopause is addressed first. Our guide on the signs you may need HRT covers when broader hormone care fits.
Safety and what to watch for
When testosterone for women is kept inside the physiologic female range, the safety record in the studied postmenopausal HSDD population is reassuring over the trial periods examined. The side effects that do appear, acne, oily skin, and increased facial or body hair, are usually dose-related and reversible when the dose comes down. They are signals of overshooting the physiologic window, which is exactly why monitoring exists.
What the evidence does not support is using testosterone as a general anti-aging or energy tonic, or stacking high doses chasing a body-composition effect. The long-term safety data at higher-than-physiologic doses in women simply are not there, and pellets that release unpredictable amounts are a particular concern because they can push levels well above the female range and stay there for months. The consensus statement specifically cautioned against formulations and doses that produce male-range concentrations in women.
How this connects to broader hormone care
Testosterone rarely acts alone. For many women the question of low testosterone arises in the middle of the menopause transition, when estrogen and progesterone are also shifting. That is why female hormone care, sometimes delivered as bioidentical hormone therapy, is evaluated as a whole rather than one hormone at a time. The male version of this conversation, including why testosterone is technically a steroid, is covered in is TRT a steroid, though the female dosing and evidence are entirely separate.
The bottom line
Low testosterone in women is a real phenomenon with real symptoms, but it sits in a gray zone: imperfect testing, one solid evidence-based indication, and a lot of marketing noise around the rest. The responsible path is a careful evaluation that looks at your full hormonal and women's health picture, treats the strongest evidence first, and monitors levels so therapy stays physiologic.
Take the 2-minute KAYU assessment and a California-licensed clinician will review your goals and labs.
This article is educational. It is not medical advice and does not substitute for a provider-patient relationship. A KAYU clinician will evaluate your individual history before recommending any treatment.